Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)
Public ClinicalTrials.gov record NCT02440464. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib After Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma (BMT CTN 1302)
Study identification
- NCT ID
- NCT02440464
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Enrollment
- 57 participants
Conditions and interventions
Conditions
Interventions
- Allogeneic HSCT Procedure
- Fludarabine Drug
- Melphalan Drug
- Bortezomib Drug
- Ixazomib Drug
- Placebo Drug
Procedure · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2015
- Primary completion
- Sep 30, 2020
- Completion
- Sep 30, 2020
- Last update posted
- Jan 3, 2023
2015 – 2020
United States locations
- U.S. sites
- 15
- U.S. states
- 13
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama | Birmingham | Alabama | 35294 | — |
| City of Hope National Medical Center | Duarte | California | 91010 | — |
| H. Lee Moffitt Cancer Center | Tampa | Florida | 33624 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| BMT Northside | Atlanta | Georgia | 30342 | — |
| Loyola University Medical Center | Maywood | Illinois | 60153 | — |
| University of Kentucky | Lexington | Kentucky | 40536 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10065 | — |
| Duke University Medical Center | Durham | North Carolina | 27705 | — |
| Ohio State/Arthur G. James Cancer Hospital | Columbus | Ohio | 43210 | — |
| University of Texas /MD Anderson CRC | Houston | Texas | 77030 | — |
| West Virginia University | Morgantown | West Virginia | 26506 | — |
| University of Wisconsin Hospital & Clinics | Madison | Wisconsin | 53792 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53211 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02440464, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 3, 2023 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02440464 live on ClinicalTrials.gov.